1 article(s) from Tzakos, Andreas G
Conventional chemotherapy versus targeted chemotherapy. Black color = Solid malignant tumor; red = ...
Jump to Figure 1
A. General structural architecture of the ideal navigated drug delivery system . B. General structu...
Jump to Figure 2
Binding and penetration mechanism of iRGD. The iRGD peptide is accumulated on the surface of αv int...
Jump to Figure 3
Representative examples of anticancer drugs utilized for the construction of PDCs. The most usual c...
Jump to Figure 4
Illustration of the drug release mechanism from the self-immolative spacer PABC conjugated to a tum...
Jump to Figure 5
Structures of the PDCs named AN-152 and AN-207.
Jump to Figure 6
Structure of the PDC named AN-238.
Jump to Figure 7
Chemical structure and synthetic scheme for the PDC ANG1005. (A) ANG1005 is composed of three molec...
Jump to Figure 8
Structure of oxime linked Dau–GnRH-III conjugate with or without cathepsin B labile spacer and thei...
Jump to Figure 9
Synthesis of the most effective GnRH-III–Dau conjugate with two drug molecules .
Jump to Figure 10
Structures of the four different PDCs of D-Lys6-GnRH-I and gemcitabine (GSG, GSG2, 3G, 3G2) .
Jump to Figure 11
Structures of (A) native sunitinib; (B) SAN1 analog of sunitinib and (C) assembled PDC named SAN1GS...
Jump to Figure 12
Synthetic scheme for the formation of GSG and the unexpected side product .
Jump to Figure 13
Illustration of uncharted guanidinium peptide coupling reagent side reactions during PDCs synthesis ...
Jump to Figure 14
Putative mechanism for the formation of the uronium side product .
Jump to Figure 15
Beilstein J. Org. Chem. 2018, 14, 930–954, doi:10.3762/bjoc.14.80
Subscribe to our Latest Articles RSS Feed.
Register and get informed about new articles.
Follow the Beilstein-Institut